Life Sciences

This study provides market data for the US Urinalysis Market. Market segments include sediment and dipstick. Sediment and dipstick are further segmented by instruments and reagents. In this deliverable, market revenues, installed base units, and market share are included. Further analysis will be provided in a separate deliverable to accompany this...

This study provides market data for the US hemostasis diagnostics market. Market segments include instruments and reagents. The study also includes market revenues, installed base units, and market share for hemostasis diagnostics. A further analysis will be provided in a separate deliverable to accompany this data. The timeframe for this study is ...

This market study provides market data for the US hematology diagnostics market. Segments in the market include instruments and reagents. Instruments are further segmented by 5PD and 3PD analyzers. Market revenues, Installed base units, and market share are included in this deliverable. Further analysis will be provided in a separate deliverable to...

This study provides data for the US in vitro diagnostics (IVD) market. Hematology, hemostasis (coagulation), urinalysis, microbiology, clinical chemistry, point of care testing, molecular diagnostics, tissue diagnostics, self-monitoring blood glucose, and immunochemistry are the segments in this market. Market revenues have been included in this de...

The marketed and development product landscape for diabetes therapeutics is becoming crowded with multiple products with little differentiation. However, there is still ample room for growth through the introduction of novel therapies that fill therapeutic gaps left by available products. Comprehensive information on market background and global ...

A complete companion diagnostic market analysis must include both developers of targeted drugs and developers of companion diagnostic tests. This research deliverable discusses important trends in the U.S. companion diagnostics market including emerging opportunities with novel drug classes and new clinical markers like circulating tumor cells. Eme...

This study aims to cover the regulatory outlook and the diagnostics and drug approval process in the US, Europe, India, China, Japan and Brazil. Comparative analysis enables competitors to understand various regulatory hurdles and to position their products in pipeline better and plan for costs. Comparative analysis also enables an understanding of...

Ongoing technology and clinical advances in every imaging modality continue to bring advanced visualization (AV) and clinical applications to centerstage. AV is not just a core step in the interpretation workflow of each of these modalities, but essentially the set of solutions that allows to realize the promises of the advances on the equipment si...

This issue of Vital Signs, released on March 31, 2014, discusses the premium price tag of Gileads Sovaldi, Sonys genomic partnership with Illumina, and Craig Venters latest venture, Human Longevity, Inc.